Drugs / Maplirpacept
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05896774 | Jun 2023 → Nov 2024 | non-Hodgkin lymphoma, plasma cell myeloma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05675449 | Dec 2022 → Jul 2025 overdue | plasma cell myeloma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05567887 | Nov 2022 → Oct 2024 | plasma cell myeloma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05139225 | Oct 2021 → Jul 2026 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03530683 | May 2018 → Jul 2024 | acute myeloid leukemia, diffuse large B-cell lymphoma, plasma cell myeloma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05896163 | Aug 2023 → Apr 2026 | diffuse large B-cell lymphoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05626322 | Aug 2023 → Aug 2024 | diffuse large B-cell lymphoma | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT05261490 | Aug 2022 → Oct 2023 | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05507541 | Apr 2023 → Jul 2027 expected | ALK-positive large B-cell lymphoma, B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma with chronic inflammation +5 | Mayo Clinic | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-13 | Incyte Corporation | Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47 incyte.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | maplirpacept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05261490 ↗ |
| Known as | PF-07901801 | “The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood cancers:” NCT03530683 ↗3“maplirpacept (PF-07901801) administered in combination with PLD” NCT05261490 ↗ “maplirpacept (PF-07901801)” NCT05896163 ↗ “maplirpacept (PF-07901801)” NCT05567887 ↗ |
| Known as | SIRP.ALPHA.-IGG4 F | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802185 ↗ |
| Known as | TTI-622 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05139225 ↗ |
| Action | Inhibit | “Neutralization of the inhibitory CD47 signal” NCT05567887 ↗ |
| Modality | Protein / enzyme biologic | “CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-622)” NCT05139225 ↗ |
| Route | Intravenous | “maplirpacept (PF-07901801) will be administered by intravenous infusion” NCT03530683 ↗ |
| Target | CD47 | “preventing CD47 from delivering its antiphagocytic signal” NCT05567887 ↗ |